Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine and Denileukin Difitox in Melanoma
NCT00056134Phase 2Completed
- Sponsor
- University Hospital Erlangen
- Start
- Oct 2002
- Primary completion
- Oct 2011
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine in melanoma, sponsored by University Hospital Erlangen. Primary endpoints: Safety and tolerability and Overall Survival. Started Oct 2002; status: completed.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00056134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056134.